The global diabetic foot ulcer treatment market size accounted for USD 9.13 billion in 2024, grew to USD 9.67 billion in 2025 and is predicted to surpass around USD 16.19 billion by 2034, representing a healthy CAGR of 5.90% between 2024 and 2034. The North America diabetic foot ulcer treatment market size is calculated at USD 4.93 billion in 2024 and is expected to grow at a fastest CAGR of 5.99% during the forecast year.
1.1. Research Objective
1.2. Scope of the Study
1.3. Definition
2.1. Research Approach
2.2. Data Sources
2.3. Assumptions & Limitations
3.1. Market Snapshot
4.1. Introduction
4.2. Market Classification and Scope
4.3. Industry Value Chain Analysis
4.3.1. Raw Material Procurement Analysis
4.3.2. Sales and Distribution Channel Analysis
4.3.3. Downstream Buyer Analysis
5.1. COVID-19 Landscape: Diabetic Foot Ulcer Treatment Industry Impact
5.2. COVID 19 - Impact Assessment for the Industry
5.3. COVID 19 Impact: Global Major Government Policy
5.4. Market Trends and Opportunities in the COVID-19 Landscape
6.1. Market Dynamics
6.1.1. Market Drivers
6.1.2. Market Restraints
6.1.3. Market Opportunities
6.2. Porter’s Five Forces Analysis
6.2.1. Bargaining power of suppliers
6.2.2. Bargaining power of buyers
6.2.3. Threat of substitute
6.2.4. Threat of new entrants
6.2.5. Degree of competition
7.1.1. Company Market Share/Positioning Analysis
7.1.2. Key Strategies Adopted by Players
7.1.3. Vendor Landscape
7.1.3.1. List of Suppliers
7.1.3.2. List of Buyers
8.1. Diabetic Foot Ulcer Treatment Market, by Type, 2024-2034
8.1.1. Advanced Wound Care
8.1.1.1. Market Revenue and Forecast (2021-2034)
8.1.2. Biologics
8.1.2.1. Market Revenue and Forecast (2021-2034)
8.1.3. Dressings
8.1.3.1. Market Revenue and Forecast (2021-2034)
9.1. Diabetic Foot Ulcer Treatment Market, by Ulcer Type, 2024-2034
9.1.1. Neuropathic Ulcers
9.1.1.1. Market Revenue and Forecast (2021-2034)
9.1.2. Neuro-ischemic Ulcers
9.1.2.1. Market Revenue and Forecast (2021-2034)
9.1.3. Neuro-ischemic Ulcers
9.1.3.1. Market Revenue and Forecast (2021-2034)
10.1. Diabetic Foot Ulcer Treatment Market, by Grade, 2024-2034
10.1.1. Grade 1
10.1.1.1. Market Revenue and Forecast (2021-2034)
10.1.2. Grade 2
10.1.2.1. Market Revenue and Forecast (2021-2034)
10.1.3. Grade 3
10.1.3.1. Market Revenue and Forecast (2021-2034)
10.1.4. Grade 4
10.1.4.1. Market Revenue and Forecast (2021-2034)
10.1.5. Grade 5
10.1.5.1. Market Revenue and Forecast (2021-2034)
11.1. Diabetic Foot Ulcer Treatment Market, by Treatment Type, 2024-2034
11.1.1. Wound Care Dressings
11.1.1.1. Market Revenue and Forecast (2021-2034)
11.1.2. Wound Care Devices
11.1.2.1. Market Revenue and Forecast (2021-2034)
11.1.3. Active Therapies
11.1.3.1. Market Revenue and Forecast (2021-2034)
11.1.4. Others
11.1.4.1. Market Revenue and Forecast (2021-2034)
12.1. Diabetic Foot Ulcer Treatment Market, by End User, 2024-2034
12.1.1. Hospitals
12.1.1.1. Market Revenue and Forecast (2021-2034)
12.1.2. Home Care
12.1.2.1. Market Revenue and Forecast (2021-2034)
12.1.3. Ambulatory Surgical Center
12.1.3.1. Market Revenue and Forecast (2021-2034)
13.1. North America
13.1.1. Market Revenue and Forecast, by Type (2021-2034)
13.1.2. Market Revenue and Forecast, by Ulcer Type (2021-2034)
13.1.3. Market Revenue and Forecast, by Grade (2021-2034)
13.1.4. Market Revenue and Forecast, by Treatment Type (2021-2034)
13.1.5. Market Revenue and Forecast, by End User (2021-2034)
13.1.6. U.S.
13.1.6.1. Market Revenue and Forecast, by Type (2021-2034)
13.1.6.2. Market Revenue and Forecast, by Ulcer Type (2021-2034)
13.1.6.3. Market Revenue and Forecast, by Grade (2021-2034)
13.1.6.4. Market Revenue and Forecast, by Treatment Type (2021-2034)
13.1.7. Market Revenue and Forecast, by End User (2021-2034)
13.1.8. Rest of North America
13.1.8.1. Market Revenue and Forecast, by Type (2021-2034)
13.1.8.2. Market Revenue and Forecast, by Ulcer Type (2021-2034)
13.1.8.3. Market Revenue and Forecast, by Grade (2021-2034)
13.1.8.4. Market Revenue and Forecast, by Treatment Type (2021-2034)
13.1.8.5. Market Revenue and Forecast, by End User (2021-2034)
13.2. Europe
13.2.1. Market Revenue and Forecast, by Type (2021-2034)
13.2.2. Market Revenue and Forecast, by Ulcer Type (2021-2034)
13.2.3. Market Revenue and Forecast, by Grade (2021-2034)
13.2.4. Market Revenue and Forecast, by Treatment Type (2021-2034)
13.2.5. Market Revenue and Forecast, by End User (2021-2034)
13.2.6. UK
13.2.6.1. Market Revenue and Forecast, by Type (2021-2034)
13.2.6.2. Market Revenue and Forecast, by Ulcer Type (2021-2034)
13.2.6.3. Market Revenue and Forecast, by Grade (2021-2034)
13.2.7. Market Revenue and Forecast, by Treatment Type (2021-2034)
13.2.8. Market Revenue and Forecast, by End User (2021-2034)
13.2.9. Germany
13.2.9.1. Market Revenue and Forecast, by Type (2021-2034)
13.2.9.2. Market Revenue and Forecast, by Ulcer Type (2021-2034)
13.2.9.3. Market Revenue and Forecast, by Grade (2021-2034)
13.2.10. Market Revenue and Forecast, by Treatment Type (2021-2034)
13.2.11. Market Revenue and Forecast, by End User (2021-2034)
13.2.12. France
13.2.12.1. Market Revenue and Forecast, by Type (2021-2034)
13.2.12.2. Market Revenue and Forecast, by Ulcer Type (2021-2034)
13.2.12.3. Market Revenue and Forecast, by Grade (2021-2034)
13.2.12.4. Market Revenue and Forecast, by Treatment Type (2021-2034)
13.2.13. Market Revenue and Forecast, by End User (2021-2034)
13.2.14. Rest of Europe
13.2.14.1. Market Revenue and Forecast, by Type (2021-2034)
13.2.14.2. Market Revenue and Forecast, by Ulcer Type (2021-2034)
13.2.14.3. Market Revenue and Forecast, by Grade (2021-2034)
13.2.14.4. Market Revenue and Forecast, by Treatment Type (2021-2034)
13.2.15. Market Revenue and Forecast, by End User (2021-2034)
13.3. APAC
13.3.1. Market Revenue and Forecast, by Type (2021-2034)
13.3.2. Market Revenue and Forecast, by Ulcer Type (2021-2034)
13.3.3. Market Revenue and Forecast, by Grade (2021-2034)
13.3.4. Market Revenue and Forecast, by Treatment Type (2021-2034)
13.3.5. Market Revenue and Forecast, by End User (2021-2034)
13.3.6. India
13.3.6.1. Market Revenue and Forecast, by Type (2021-2034)
13.3.6.2. Market Revenue and Forecast, by Ulcer Type (2021-2034)
13.3.6.3. Market Revenue and Forecast, by Grade (2021-2034)
13.3.6.4. Market Revenue and Forecast, by Treatment Type (2021-2034)
13.3.7. Market Revenue and Forecast, by End User (2021-2034)
13.3.8. China
13.3.8.1. Market Revenue and Forecast, by Type (2021-2034)
13.3.8.2. Market Revenue and Forecast, by Ulcer Type (2021-2034)
13.3.8.3. Market Revenue and Forecast, by Grade (2021-2034)
13.3.8.4. Market Revenue and Forecast, by Treatment Type (2021-2034)
13.3.9. Market Revenue and Forecast, by End User (2021-2034)
13.3.10. Japan
13.3.10.1. Market Revenue and Forecast, by Type (2021-2034)
13.3.10.2. Market Revenue and Forecast, by Ulcer Type (2021-2034)
13.3.10.3. Market Revenue and Forecast, by Grade (2021-2034)
13.3.10.4. Market Revenue and Forecast, by Treatment Type (2021-2034)
13.3.10.5. Market Revenue and Forecast, by End User (2021-2034)
13.3.11. Rest of APAC
13.3.11.1. Market Revenue and Forecast, by Type (2021-2034)
13.3.11.2. Market Revenue and Forecast, by Ulcer Type (2021-2034)
13.3.11.3. Market Revenue and Forecast, by Grade (2021-2034)
13.3.11.4. Market Revenue and Forecast, by Treatment Type (2021-2034)
13.3.11.5. Market Revenue and Forecast, by End User (2021-2034)
13.4. MEA
13.4.1. Market Revenue and Forecast, by Type (2021-2034)
13.4.2. Market Revenue and Forecast, by Ulcer Type (2021-2034)
13.4.3. Market Revenue and Forecast, by Grade (2021-2034)
13.4.4. Market Revenue and Forecast, by Treatment Type (2021-2034)
13.4.5. Market Revenue and Forecast, by End User (2021-2034)
13.4.6. GCC
13.4.6.1. Market Revenue and Forecast, by Type (2021-2034)
13.4.6.2. Market Revenue and Forecast, by Ulcer Type (2021-2034)
13.4.6.3. Market Revenue and Forecast, by Grade (2021-2034)
13.4.6.4. Market Revenue and Forecast, by Treatment Type (2021-2034)
13.4.7. Market Revenue and Forecast, by End User (2021-2034)
13.4.8. North Africa
13.4.8.1. Market Revenue and Forecast, by Type (2021-2034)
13.4.8.2. Market Revenue and Forecast, by Ulcer Type (2021-2034)
13.4.8.3. Market Revenue and Forecast, by Grade (2021-2034)
13.4.8.4. Market Revenue and Forecast, by Treatment Type (2021-2034)
13.4.9. Market Revenue and Forecast, by End User (2021-2034)
13.4.10. South Africa
13.4.10.1. Market Revenue and Forecast, by Type (2021-2034)
13.4.10.2. Market Revenue and Forecast, by Ulcer Type (2021-2034)
13.4.10.3. Market Revenue and Forecast, by Grade (2021-2034)
13.4.10.4. Market Revenue and Forecast, by Treatment Type (2021-2034)
13.4.10.5. Market Revenue and Forecast, by End User (2021-2034)
13.4.11. Rest of MEA
13.4.11.1. Market Revenue and Forecast, by Type (2021-2034)
13.4.11.2. Market Revenue and Forecast, by Ulcer Type (2021-2034)
13.4.11.3. Market Revenue and Forecast, by Grade (2021-2034)
13.4.11.4. Market Revenue and Forecast, by Treatment Type (2021-2034)
13.4.11.5. Market Revenue and Forecast, by End User (2021-2034)
13.5. Latin America
13.5.1. Market Revenue and Forecast, by Type (2021-2034)
13.5.2. Market Revenue and Forecast, by Ulcer Type (2021-2034)
13.5.3. Market Revenue and Forecast, by Grade (2021-2034)
13.5.4. Market Revenue and Forecast, by Treatment Type (2021-2034)
13.5.5. Market Revenue and Forecast, by End User (2021-2034)
13.5.6. Brazil
13.5.6.1. Market Revenue and Forecast, by Type (2021-2034)
13.5.6.2. Market Revenue and Forecast, by Ulcer Type (2021-2034)
13.5.6.3. Market Revenue and Forecast, by Grade (2021-2034)
13.5.6.4. Market Revenue and Forecast, by Treatment Type (2021-2034)
13.5.7. Market Revenue and Forecast, by End User (2021-2034)
13.5.8. Rest of LATAM
13.5.8.1. Market Revenue and Forecast, by Type (2021-2034)
13.5.8.2. Market Revenue and Forecast, by Ulcer Type (2021-2034)
13.5.8.3. Market Revenue and Forecast, by Grade (2021-2034)
13.5.8.4. Market Revenue and Forecast, by Treatment Type (2021-2034)
13.5.8.5. Market Revenue and Forecast, by End User (2021-2034)
14.1. ConvaTec Group Plc
14.1.1. Company Overview
14.1.2. Product Offerings
14.1.3. Financial Performance
14.1.4. Recent Initiatives
14.2. 3M
14.2.1. Company Overview
14.2.2. Product Offerings
14.2.3. Financial Performance
14.2.4. Recent Initiatives
14.3. B. Braun Melsungen AG
14.3.1. Company Overview
14.3.2. Product Offerings
14.3.3. Financial Performance
14.3.4. Recent Initiatives
14.4. Medline Industries, Inc.
14.4.1. Company Overview
14.4.2. Product Offerings
14.4.3. Financial Performance
14.4.4. Recent Initiatives
14.5. Coloplast Group
14.5.1. Company Overview
14.5.2. Product Offerings
14.5.3. Financial Performance
14.5.4. Recent Initiatives
14.6. Smith & Nephew
14.6.1. Company Overview
14.6.2. Product Offerings
14.6.3. Financial Performance
14.6.4. Recent Initiatives
14.7. Cardinal Health Inc
14.7.1. Company Overview
14.7.2. Product Offerings
14.7.3. Financial Performance
14.7.4. Recent Initiatives
14.8. Organogenesis Inc
14.8.1. Company Overview
14.8.2. Product Offerings
14.8.3. Financial Performance
14.8.4. Recent Initiatives
14.9. URGO
14.9.1. Company Overview
14.9.2. Product Offerings
14.9.3. Financial Performance
14.9.4. Recent Initiatives
14.10. Kerecis
14.10.1. Company Overview
14.10.2. Product Offerings
14.10.3. Financial Performance
14.10.4. Recent Initiatives
15.1. Primary Research
15.2. Secondary Research
15.3. Assumptions
16.1. About Us
16.2. Glossary of Terms
No cookie-cutter, only authentic analysis – take the 1st step to become a Precedence Research client
Report Description
Get a Sample